BofA Securities, Leerink Partners, Evercore ISI, and RBC Capital Markets are acting as book-running managers for the proposed offering.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on CRBU:
- Caribou Biosciences Announces Pricing of Upsized $125 Million Public Offering
- Caribou Biosciences Reports Positive Clinical Data from Dose Escalation of CB-010 ANTLER Phase 1 Trial in r/r B-NHL
- Caribou Biosciences Announces Proposed Public Offering of Common Stock
- Allogene Therapeutics price target lowered to $18 from $20 at Truist
- Caribou Biosciences initiated with a Buy at Truist